 Syndax Pharmaceuticals Inc NASDAQ: SNDX and Incyte Corporation NASDAQ: INCY have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndaxs axatilimab. Related Content: Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs. 